[1]陈贵兵,欧阳忠,韩成坤,等.99Tcm-3PRGD2整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比研究[J].国际放射医学核医学杂志,2017,41(1):1-7.[doi:10.3760/cma.j.issn.1673-4114.2017.01.001]
　Chen Guibing,Ouyang Zhong,Han Chengkun,et al.Evaluation of 99Tcm-3PRGD2 integrin receptor imaging in qualitative diagnosis of breast cancer and its comparison with mammography[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):1-7.[doi:10.3760/cma.j.issn.1673-4114.2017.01.001]
点击复制

99Tcm-3PRGD2整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第1期
页码:
1-7
栏目:
论著
出版日期:
2017-01-25

文章信息/Info

Title:
Evaluation of 99Tcm-3PRGD2 integrin receptor imaging in qualitative diagnosis of breast cancer and its comparison with mammography
作者:
陈贵兵1;  欧阳忠2;  韩成坤3;  黄劲雄1;  何小江1;  王凡4;  贾兵4;  吴华1
1. 361003, 厦门大学附属第一医院核医学科;
2. 361003, 厦门大学附属第一医院乳腺外科;
3. 361003, 厦门大学附属第一医院放射科;
4. 100191, 北京大学医学同位素研究中心
Author(s):
Chen Guibing1;  Ouyang Zhong2;  Han Chengkun3;  Huang Jinxiong1;  He Xiaojiang1;  Wang Fan4;  Jia Bing4;  Wu Hua1
1. Department of Nuclear Medicine, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China;
2. Department of Breast Surgery, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China;
3. Department of Radiology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China;
4. Medical Isotopes Research Center, Peking University, Beijing 100191, China
关键词:
乳腺肿瘤; 体层摄影术; 发射型计算机; 单光子; 体层摄影术; X线计算机; 钼靶; 整合素αvβ3受体; 分子显像
Keywords:
Breast neoplasms; Tomography; emission-computed; single-phton; Tomography; X-ray computed; Mammography; Integrin αvβ3 receptor; Molecular imaging
DOI:
10.3760/cma.j.issn.1673-4114.2017.01.001
摘要:
目的 研究99Tcm-联肼尼克酰胺-3聚乙二醇-精氨酸-甘氨酸-天冬氨酸环肽二聚体（99Tcm-3PRGD2）整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比。方法 选取初诊乳腺占位患者84例，均为女性。所有患者行2 h、4 h 99Tcm-3PRGD2 整合素受体显像及钼靶检查，以术后病理结果作为“金标准”，比较不同显像方法（全身显像及胸部SPECT/CT显像）对乳腺癌定性诊断的价值，并与钼靶结果进行对比分析。采用SPSS22.0软件，对数据进行t检验和χ2检验。结果 SPECT/CT显像的诊断效能高于全身显像；乳腺癌99Tcm-3PRGD2摄取率[病灶容积最大计数（Tmax）、病灶容积平均计数（Tmean）、Tmax/本底平均计数（B）值及Tmean/B值]均明显高于良性占位（t=2.09~3.19，均P<0.05），且Tmax/B值差异更为明显（t=3.19，P<0.01）；2 h、4 h显像对乳腺癌诊断效能差异无统计学意义（t=0.63~1.25，均P>0.05）。SPECT/CT显像诊断乳腺癌的灵敏度大于95.0%，联用钼靶后灵敏度可以提高到98.4%；对致密型乳腺患者，SPECT/CT显像与钼靶诊断乳腺癌的灵敏度、特异度、准确率分别为95.2%、83.3%、91.7%和78.6%、76.2%、77.8%，前者的准确率高于后者，且差异有统计学意义（χ2=4.341，P<0.05）。结论 99Tcm-3PRGD2 SPECT/CT显像定性诊断乳腺癌具有高灵敏度，是对钼靶的有益补充，尤其对致密型乳腺占位患者具有独特优势。
Abstract:
Objective To evaluate the value of 99Tcm-3PRGD2 integrin receptor imaging in qualitative diagnosis of breast cancer and then compare this technique with mammography. Methods A total of 84 female patients with established breast lesions were recruited. All patients were examined using 99Tcm-3PRGD2 integrin receptor imaging and mammography. Diagnosis of breast(especially dense breast) lesion by using these two techniques was analyzed and compared with postoperative pathology as the gold standard. T test and χ2 test were used for data statistical analysis by using SPSS22.0 software. Results The diagnostic efficiency of SPECT/CT imaging was higher than that of whole-body imaging. The intake rates of Tmax, Tmean, Tmean/B, and Tmax/B were significantly higher in breast cancer than in benign nodules(t=2.09~3.19, all P<0.05), and their difference in intake of Tmax/B was obvious(t=3.19, P<0.01). The difference between 2 and 4 h imaging was not significant(t=0.63~1.25, all P>0.05). The sensitivity of SPECT/CT in diagnosis of breast cancer was more than 95.0%, which could be increased to 98.4% when this technique was combined with mammography. For dense mammary gland, the sensitivity, specificity, and accuracy of 99Tcm-3PRGD2 SPECT/CT and mammography were 95.2%, 83.3%, and 91.7% and 78.6%, 76.2%, and 77.8%, respectively, 99Tcm-3PRGD2 SPECT/CT had a higher accuracy(χ2=4.341, P<0.05). Conclusions 99Tcm-3PRGD2 SPECT/CT had high sensitivity and was a useful complement to mammography. This technique demonstrated a higher diagnostic value than mammography for qualitative diagnosis of dense mammary gland.

参考文献/References:

[1] Desantis C, Ma JM, Bryan L, et al.Breast cancer statistics, 2013[J].CA Cancer J Clin, 2014, 64(1):52-62.DOI:10.3322/caac.21203.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2015[J].CA Cancer J Clin, 2015, 65(1):5-29.DOI:10.3322/caac.21254.
[3] 孙强.乳腺癌多学科综合治疗模式中手术治疗的核心作用[J/CD].中华乳腺病杂志:电子版, 2012, 6(1):9-15[2016-08-03].http://www.zhrxbzz.com/oa/DArticle.aspx?type=view&id=20120102.DOI:10.3877/cma.j.issn.1674-0807.2012.01.002. Sun Q.Multidisciplinary comprehensive therapy of breast cancer surgical treatment of the core role model[J].Chin J Breast Dis (Electronic Version), 2012, 6(1):9-15[2016-08-03].http://www.zhrxbzz.com/oa/DArticle.aspx?type=view&id=20120102.
[4] Eifel P, Axelson JA, Costa J, et al.National institutes of health consensus development conference statement:adjuvant therapy for breast cancer, November 1-3, 2000[J].J Natl Cancer Inst, 2001, 93(13):979-989.DOI:10.1093/jnci/93.13.979.
[5] Buscombe JR, Cwikla JB, Holloway B, et al.Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves[J].J Nucl Med, 2001, 42(1):3-8.
[6] Murphy IG, Dillon MF, Doherty AO, et al.Analysis of patients with false negative mammography and symptomatic breast carcinoma[J].J Surg Oncol, 2007, 96(6):457-463.DOI:10.1002/jso.20801.
[7] Liberman M, Sampalis F, Mulder DS, et al.Breast cancer diagnosis by scintimammography:a meta-analysis and review of the literature[J].Breast Cancer Res Treat, 2003, 80(1):115-126.DOI:10.1023/A:1024417331304.
[8] 王健, 宋秀宇, 徐文贵, 等.乳腺癌放射性核素分子成像研究进展[J].国际医学放射学杂志, 2015, 38(4):361-365.DOI:10.3874/j.issn.1674-1897.2015.04.Z0411.Wang J, Song XY, Xu WG, et al.The research progress of radionuclide molecular imaging for breast cancer[J].Int J Med Radiol, 2015, 38(4):361-365.
[9] 何小江, 黄劲雄, 陈贵兵, 等.99mTc-奥曲肽和X线钼靶诊断乳腺癌[J].中国医学影像技术, 2009, 25(10):1892-1895.DOI:10.3321/j.issn:1003-3289.2009.10.044.He XJ, Huang JX, Chen GB, et al.99mTc-octreotide scintigraphy and planar X-ray mammography diagnosis of breast cancer[J].Chin J Med Imaging Technol, 2009, 25(10):1892-1895.
[10] 张金山, 邓念英, 李舜, 等.99Tcm-octreotide显像在乳腺癌诊断中的应用[J].中华核医学杂志, 2004, 24(1):24-26.DOI:10.3760/cma.j.issn.2095-2848.2004.01.008.Zhang JS, Deng NY, Li S, et al.Primary application of 99Tcm-octreotide imaging in the diagnosis of breast cancer[J].Chin J Nucl Med, 2004, 24(1):24-26.
[11] 黄为昆, 李国新, 齐德林.乳腺癌及腋淋巴结转移99Tcm-tetrofosmin与99Tcm-MIBI显像的对比研究[J].中华核医学杂志, 2001, 21(2):95-96.DOI:10.3760/cma.j.issn.2095-2848.2001.02.015.Huang WK, Li GX, Qi DL.A clinical comparative study of 99Tcm-tetrofosmin with 99Tcm-MIBI in breast carcinoma and axillary lymph node metastases[J].Chin J Nucl Med, 2001, 21(2):95-96.
[12] Haubner RH, Wester HJ, Weber WA, et al.Radiotracer-based strategies to image angiogenesis[J].Q J Nucl Med, 2003, 47(3):189-199.
[13] 江泽飞, 邵志敏, 徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识[J].中华肿瘤杂志, 2010, 32(2):158-160.DOI:10.3760/cma.j.issn.0253-3766.2010.02.018.Jiang ZF, Shao ZM, Xu BH.Diagnosis and treatment of HER-2-positive breast cancer:expert consensus of the chinese anti-cancer association[J].Chin J Oncol, 2010, 32(2):158-160.
[14] Hood JD, Cheresh DA.Role of integrins in cell invasion and migration[J].Nat Rev Cancer, 2002, 2(2):91-100.DOI:10.1038/nrc727.
[15] Desgrosellier JS, Cheresh DA.Integrins in cancer:biological implications and therapeutic opportunities[J].Nat Rev Cancer, 2010, 10(1):9-22.DOI:10.1038/nrc2748.
[16] Niu G, Chen X.Why integrin as a primary target for imaging and therapy[J].Theranostics, 2011, 1(1):30-47.DOI:10.7150/thno/v01p0030.
[17] Shi JY, Wang LJ, Kim YS, et al.99mTcO(MAG2-3G3-dimer):a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics[J].Eur J Nucl Med Mol Imaging, 2009, 36(11):1874-1884.DOI:10.1007/s00259-009-1166-1.
[18] Wang L, Shi J, Kim YS, et al.Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers[J].Mol Pharm, 2009, 6(1):231-245.DOI:10.1021/mp800150r.
[19] Shi J, Kim YS, Chakraborty S, et al.2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers:effect of technetium chelate on tumor uptake and pharmacokinetics[J].Bioconjug Chem, 2009, 20(8):1559-1568.DOI:10.1021/bc9001739.
[20] Liu Z, Jia B, Shi J, et al.Tumor uptake of the RGD dimeric probe 99mTc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature[J].Bioconjug Chem, 2010, 21(3):548-555.DOI:10.1021/bc900547d.
[21] Jia B, Liu Z, Zhu Z, et al.Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD2 in non-human primates[J].Mol Imaging Biol, 2011, 13(4):730-736.DOI:10.1007/s11307-010-0385-y.
[22] Zhu Z, Miao W, Li Q, et al.99mTc-3PRGD2 for integrin receptor imaging of lung cancer:a multicenter study[J].J Nucl Med, 2012, 53(5):716-722.DOI:10.2967/jnumed.111.098988.
[23] Liu L, Song Y, Gao S, et al.99mTc-3PRGD2 scintimammography in palpable and nonpalpable breast lesions[J/OL].Mol Imaging, 2014, 13:1-7[2016-08-03].https://www.ncbi.nlm.nih.gov/pubmed/?term=24825112.DOI:10.2310/7290.2014.00010.
[24] Ma Q, Chen B, Gao S, et al.99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions:comparative study with 99mTc-MIBI[J/OL].PLoS One, 2014, 9(9):e0108349[2016-08-03].http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108349.DOI:10.1371/journal.pone.0108349.
[25] Chen Q, Ma Q, Chen M, et al.An exploratory study on 99mTc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to 99mTc-3P4-RGD2[J/OL].PLoS One, 2015, 10(4):e0123401[2016-08-03].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388716.DOI:10.1371/journal.pone.0123401.
[26] Zhou Y, Kim YS, Chakraborty S, et al.99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVβ3 expression[J].Mol Imaging, 2011, 10(5):386-397.DOI:10.2310/7290.2011.00006.
[27] Ma Q, Ji B, Jia B, et al.Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy[J].Eur J Nucl Med Mol Imaging, 2011, 38(12):2145-2152.DOI:10.1007/s00259-011-1901-2.
[28] Percha B, Nassif H, Lipson J, et al.Automatic classification of mammography reports by BI-RADS breast tissue composition class.J Am Med Inform Assoc, 2012, 19(5):913-916.DOI:10.1136/amiajnl-2011-000607.
[29] Palmedo H, Schomburg A, Grünwald F, et al.Technetium-99m-MIBI scintimammography for suspicious breast lesions[J].J Nucl Med, 1996, 37(4):626-630.
[30] Scopinaro F, Schillaci O, Ussof W, et al.A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography[J].Anticancer Res, 1997, 17(3B):1631-1634.
[31] Pichler BJ, Kneilling M, Haubner R, et al.Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD[J].J Nucl Med, 2005, 46(1):184-189.
[32] Mcdonald DM, Choyke PL.Imaging of angiogenesis:from microscope to clinic[J].Nat Med, 2003, 9(6):713-725.DOI:10.1038/nm0603-713.
[33] Horton MA.The αvβ3 integrin "vitronectin receptor"[J].Int J Biochem Cell Biol, 1997, 29(5):721-725.DOI:10.1016/S1357-2725(96)00155-0.

相似文献/References:

[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
　Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
　Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
　Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
　Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
　Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
　Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
　Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
　Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[9]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
　Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[10]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[11]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
　Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[12]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
　Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[13]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
　Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
[14]王宇峰,刘海娜,张居洋,等.SPECT/CT融合显像对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2014,38(6):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
　Wang Yu-feng,Liu Hai-na,Zhang Ju-yang,et al.Clinical value of SPECT/CT fusion imaging in diagnosing metastatic bone lesions in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
[15]董佳佳,章斌.多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较[J].国际放射医学核医学杂志,2014,38(6):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
　Dong Jia-jia,Zhang Bin.Comparision on the values of different image modalities in monitoring the response to neoadjuvant chemotherapy in breast cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
[16]袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
　YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
[17]袁建伟,杨劼,贺小红,等.18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值[J].国际放射医学核医学杂志,2013,37(4):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
　YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Diagnosis value of 18F-FDG PET/CT and 3.0T MRI combined imaging in detecting the primary focus of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
[18]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
　LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[19]樊孝廉,鲁胜男,古炎发,等.乳腺癌患者骨病灶SPECT/CT融合显像的临床价值[J].国际放射医学核医学杂志,2013,37(4):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
　FAN Xiao-lian,LU Sheng-nan,GU Yan-fa,et al.The clinical value of SPECT/CT fusion imaging in the diagnosis of bone metastasis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
[20]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
　LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]

备注/Memo

备注/Memo:
收稿日期:2016-08-03。
基金项目:福建省自然科学基金（2015J01565）；厦门市科技惠民计划项目（3502Z20134008）
通讯作者:吴华,Email:wuhua1025@163.com
更新日期/Last Update: 1900-01-01